Cell line · CVCL_0539
Papers82
1 to 20 of 82
Download this page as JSON| Paper | Journal | Year | How we know | Retracted | Source |
|---|---|---|---|---|---|
| SIRT2 deacylase modulators control B cell metabolic reprogramming in EBV infection and mitogenic activation. | Proc Natl Acad Sci U S A | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Enhanced efficacy of a specific HDAC3 inhibitor in combination with 5-azacitidine against diffuse large B-cell lymphoma. | Blood Neoplasia | 2026 | Its Methods give the RRID and name the line | PubMed | |
| The Growth Supporting Role of ZDHHC11 Is Linked to the MEF2B-BCL6 Regulatory Circuit in Burkitt Lymphoma. | Int J Cancer | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Reconstruction of T cell infiltration in an osteosarcoma PDX-organoid interactive biobank for personalized immunotherapy. | Cell Rep Med | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Aberrant SUMOylation Restricts the Targetable Cancer Immunopeptidome. | Adv Sci (Weinh) | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Mass Cytometry-Based Approach for the Investigation of Stimulator of Interferon Genes Pathway. | Eur J Immunol | 2025 | Its Methods give the RRID and name the line | PubMed | |
| DUSP11 is an Intracellular Innate Immune Checkpoint in Lung Adenocarcinoma. | Cancer Immunol Res | 2025 | Its Methods give the RRID and name the line | PubMed | |
| DLBCL Cells Emerge after CD19 CAR T Cells with Cross-Antigen Resistance and a Gene Signature Predictive of Clinical CAR T-cell Response. | Blood Cancer Discov | 2025 | Its Methods give the RRID and name the line | PubMed | |
| TP53 upregulation via aurora kinase inhibition overcomes primary failure to venetoclax in BCL2-rearranged lymphomas. | iScience | 2025 | Its Methods give the RRID and name the line | PubMed | |
| MYC networks associate with decreased CD8 T-cell presence in diffuse large B-cell lymphoma and may be addressed by the synergistic combination of AZD4573 and Selinexor - a preliminary analysis. | Ann Hematol | 2025 | Its Methods give the RRID and name the line | PubMed | |
| BKT300: A Novel Anti-Leukemic Small Molecule Targeting the Protein Regulator of Cytokinesis 1 (PRC1) Pathway | Res Sq | 2025 | Its Methods give the RRID and name the line | PubMed | |
| EZH1/EZH2 inhibition enhances adoptive T cell immunotherapy against multiple cancer models. | Cancer Cell | 2025 | Its Methods give the RRID and name the line | PubMed | |
| ZBTB48 is a priming factor regulating B-cell-specific CIITA expression. | EMBO J | 2024 | Its Methods give the RRID and name the line | PubMed | |
| EZB-type diffuse large B-cell lymphoma cell lines have superior migration capabilities compared to MCD-type. | Br J Haematol | 2024 | Its Methods give the RRID and name the line | PubMed | |
| A Bruton tyrosine kinase inhibitor-resistance gene signature predicts prognosis and identifies TRIP13 as a potential therapeutic target in diffuse large B-cell lymphoma. | Sci Rep | 2024 | Its Methods give the RRID and name the line | PubMed | |
| GNAS knockout potentiates HDAC3 inhibition through viral mimicry-related interferon responses in lymphoma. | Leukemia | 2024 | Its Methods give the RRID and name the line | PubMed | |
| Molecular targets of glucocorticoids that elucidate their therapeutic efficacy in aggressive lymphomas. | Cancer Cell | 2024 | Its Methods give the RRID and name the line | PubMed | |
| Loss of CREBBP and KMT2D cooperate to accelerate lymphomagenesis and shape the lymphoma immune microenvironment. | Nat Commun | 2024 | Its Methods give the RRID and name the line | PubMed | |
| A Cluster of Evolutionarily Recent KRAB Zinc Finger Proteins Protects Cancer Cells from Replicative Stress-Induced Inflammation. | Cancer Res | 2024 | Its Methods give the RRID and name the line | PubMed | |
| 4'-Ethynyl-2'-Deoxycytidine (EdC) Preferentially Targets Lymphoma and Leukemia Subtypes by Inducing Replicative Stress. | Mol Cancer Ther | 2024 | Its Methods give the RRID and name the line | PubMed |
cell-lines-2026-11-14-0.1.0
Sources 4
- CellosaurusCC BY 4.0, with credit to Cellosaurus (SIB)
- PubMed Central's articlesTitles shown only for CC0, CC BY and public domain articles
- NLM's PMC Article DatasetsCourtesy of NLM, which does not endorse this database
- PubMedNLM's terms
Each source's terms
- CellosaurusCC BY 4.0. Cellosaurus's README: "we have chosen to apply the Creative Commons Attribution 4.0 International (CC BY 4.0) license to Cellosaurus (https://creativecommons.org/licenses/by/4.0/). This means that you are free to copy and redistribute Cellosaurus in any medium or format. You can remix, transform, and build upon Cellosaurus for any purpose, even commercially. You must give appropriate credit, provide a link to the license, and indicate if changes were made." Copyright (c) CALIPHO group, SIB Swiss Institute of Bioinformatics. Read on 14 Nov 2026 at https://ftp.expasy.org/databases/cellosaurus/README
- PubMed Central's articlesEach article's own license. Its words show only under CC0, CC BY or public domain
- NLM's PMC Article DatasetsNLM's PMC Article Datasets on AWS, https://registry.opendata.aws/ncbi-pmc. Its terms: users "acknowledge NLM as the source of the data in a clear and conspicuous manner", do not use the PubMed Central wordmark or the PMC logo, do not "indicate or imply that NLM/NIH/HHS has endorsed" a product, and "only distribute data that are licensed for redistribution". Each article keeps its own license: https://pmc.ncbi.nlm.nih.gov/about/copyright/
- PubMedNLM's terms
Cellosaurus, SIB Swiss Institute of Bioinformatics, https://www.cellosaurus.org, CC BY 4.0. Its problem notes are given in its own words.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/cell-lines/v1/CVCL_0539/papers